These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 10147351)

  • 1. Fluoroquinolones: use of clinical data to aid formulary choice by the system of objective judgement analysis (SOJA) method.
    Janknegt R
    Pharmacoeconomics; 1994 Jul; 6(1):15-33. PubMed ID: 10147351
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Choice of antibiotics in uncomplicated cystitis; application of 'system of objectified judgement analysis' (SOJA) method].
    Janknegt R; van den Broek PJ; Kullberg BJ; Stobberingh E
    Ned Tijdschr Geneeskd; 1999 Dec; 143(49):2466-71. PubMed ID: 10608985
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Gatifloxacin: a review of its use in the management of bacterial infections.
    Perry CM; Ormrod D; Hurst M; Onrust SV
    Drugs; 2002; 62(1):169-207. PubMed ID: 11790160
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Diagnosis and treatment of community-acquired and hospital-acquired pneumonia.
    Foster MT
    Pharmacotherapy; 1993; 13(2 Pt 2):45S-50S. PubMed ID: 8474938
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The System of Objectified Judgement Analysis (SOJA). A tool in rational drug selection for formulary inclusion.
    Janknegt R; Steenhoek A
    Drugs; 1997 Apr; 53(4):550-62. PubMed ID: 9098659
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A critical review of the fluoroquinolones: focus on respiratory infections.
    Zhanel GG; Ennis K; Vercaigne L; Walkty A; Gin AS; Embil J; Smith H; Hoban DJ
    Drugs; 2002; 62(1):13-59. PubMed ID: 11790155
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prescribing considerations in fluoroquinolone therapy.
    Gentry LO
    Pharmacotherapy; 1993; 13(2 Pt 2):39S-44S. PubMed ID: 8474937
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In vitro activity of enoxacin versus ciprofloxacin, fleroxacin, lomefloxacin, ofloxacin, pefloxacin, and rufloxacin against uropathogens.
    Naber KG; Well M; Hollauer K; Kirchbauer D; Witte W
    Chemotherapy; 1998; 44(2):77-84. PubMed ID: 9551236
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Integrating fluoroquinolones into the hospital formulary.
    Bertino JS
    Pharmacotherapy; 2001 Oct; 21(10 Pt 2):273S-283S. PubMed ID: 11642692
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ofloxacin. A reappraisal of its use in the management of genitourinary tract infections.
    Onrust SV; Lamb HM; Balfour JA
    Drugs; 1998 Nov; 56(5):895-928. PubMed ID: 9829160
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparative clinical, microbiologic, and economic audit of the use of oral ciprofloxacin and parenteral antimicrobials.
    Cooke J; Cairns CJ; Tillotson GS; Conner S; Lewin SK; Nicholls J; Tredree RL; Willis JV; Hitchings CR
    Ann Pharmacother; 1993 Jun; 27(6):785-9. PubMed ID: 8329804
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Oral fluoroquinolone versus mono- or combination parenteral therapy in the management of bacterial infections: a critical appraisal.
    Guay DR
    DICP; 1990 Jan; 24(1):11-8. PubMed ID: 2405585
    [TBL] [Abstract][Full Text] [Related]  

  • 13. High-dose intravenous fluoroquinolones in the treatment of severe infections.
    Modai J
    J Chemother; 1999 Dec; 11(6):478-85. PubMed ID: 10678789
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The role of the fluoroquinolones.
    Guay DR
    Pharmacotherapy; 1992; 12(6 Pt 2):71S-85S. PubMed ID: 1480503
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacodynamics of fluoroquinolones against Streptococcus pneumoniae in patients with community-acquired respiratory tract infections.
    Ambrose PG; Grasela DM; Grasela TH; Passarell J; Mayer HB; Pierce PF
    Antimicrob Agents Chemother; 2001 Oct; 45(10):2793-7. PubMed ID: 11557471
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [In vitro activity of 3 fluoroquinolones on Branhamella catarrhalis].
    Suermondt G; Denamur E; Laurans G; Orfila J
    Pathol Biol (Paris); 1988 Jun; 36(5 Pt 2):647-50. PubMed ID: 3141885
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical and economic effect of ciprofloxacin as an alternative to injectable antimicrobial therapy.
    Powers T; Bingham DH
    Am J Hosp Pharm; 1990 Aug; 47(8):1781-4. PubMed ID: 2389785
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetics of ciprofloxacin as a tool to optimise dosage schedules in community patients.
    Sánchez Navarro MD; Coloma Milano C; Zarzuelo Castañeda A; Sayalero Marinero ML; Sánchez-Navarro A
    Clin Pharmacokinet; 2002; 41(14):1213-20. PubMed ID: 12405867
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Fluoroquinolones in animal health.
    Brown SA
    J Vet Pharmacol Ther; 1996 Feb; 19(1):1-14. PubMed ID: 8992019
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Role of oral fluoroquinolones as an alternative to traditional parenteral therapy for patients with serious infections.
    Ball P
    Clin Invest Med; 1989 Feb; 12(1):69-70. PubMed ID: 2920483
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.